Heart Failure
Authors: Christine Laine
Journal: Annals of Internal Medicine (2007)

In the Clinic4 December 2007Heart FailureChristine Laine, MD, MPH, David R. Goldmann, MD, and Jennifer F. WilsonChristine Laine, MD, MPHSearch for more papers by this author, David R. Goldmann, MDSearch for more papers by this author, and Jennifer F. WilsonSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-147-11-200712040-01012 SectionsSupplemental MaterialAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Editor's Note: This issue of In the Clinic has been updated.Approximately 5 million people in the United States have heart failure, and the number is on the rise, according to the National Heart Lung and Blood Institute. Heart failure is the most frequent cause of hospitalization in U.S. patients older than 65 years, and the disease leads to about 300 000 deaths per year (1). Heart failure is a significant problem throughout the rest of the world as well, but few accurate data are available. The most common cause of heart failure in industrialized countries is ischemic cardiomyopathy, whereas ...References1. Finn P. American Heart Association—scientific sessions 2005. 13-16 November 2005, Dallas, TX, USA. IDrugs. 2006;9:13-5. [PMID: 16374724] Google Scholar2. Kannel WB. Current status of the epidemiology of heart failure. Curr Cardiol Rep. 1999;1:11-9. [PMID: 10980814] Google Scholar3. Centers for Disease Control and Prevention (CDC). Mortality from congestive heart failure—United States, 1980-1990. MMWR Morb Mortal Wkly Rep. 1994;43:77-81. [PMID: 8295629] Google Scholar4. He J, Ogden LG, Bazzano LA, et al. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med. 2001;161:996-1002. [PMID: 11295963] Google Scholar5. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157:2413-46. [PMID: 9385294] Google Scholar6. HOPE Investigators. Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study. Circulation. 2001;104:522-6. [PMID: 11479247] Google Scholar7. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001-9. [PMID: 8801446] Google Scholar8. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med. 2001;344:501-9. [PMID: 11172193] Google Scholar9. Fadel BM, Ellahham S, Ringel MD, et al. Hyperthyroid heart disease. Clin Cardiol. 2000;23:402-8. [PMID: 10875028] Google Scholar10. Coleman HN III, Taylor RR, Pool PE, et al. Congestive heart failure following chronic tachycardia. Am Heart J. 1971;81:790-8. [PMID: 5088355] Google Scholar11. Peters KG, Kienzle MG. Severe cardiomyopathy due to chronic rapidly conducted atrial fibrillation: complete recovery after restoration of sinus rhythm. Am J Med. 1988;85:242-4. [PMID: 3400701] Google Scholar12. Grogan M, Smith HC, Gersh BJ, Wood DL. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol. 1992;69:1570-3. [PMID: 1598871] Google Scholar13. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385-90. [PMID: 11356434] Google Scholar14. Myers J, Madhavan R. Exercise testing with gas exchange analysis. Cardiol Clin. 2001;19:433-45. [PMID: 11570115] Google Scholar15. Morrison LK, Harrison A, Krishnaswamy P, et al. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol. 2002;39:202-9. [PMID: 11788208] Google Scholar16. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355(3):251-9. [PMID: 16855265] Google Scholar17. Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006;355(3):260-9. [PMID: 16855266] Google Scholar18. Sullivan MJ, Cobb FR. The anaerobic threshold in chronic heart failure. Relation to blood lactate, ventilatory basis, reproducibility, and response to exercise training. Circulation. 1990;81:II47-58. [PMID: 2295152] Google Scholar19. Myers J, Gianrossi R, Schwitter J, et al. Effect of exercise training on postexercise oxygen uptake kinetics in patients with reduced ventricular function. Chest. 2001;120:1206-11. [PMID: 11591562] Google Scholar20. Sullivan MJ, Cobb FR. Central hemodynamic response to exercise in patients with chronic heart failure. Chest. 1992;101:340S-346S. [PMID: 1576862] Google Scholar21. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-35. [PMID: 2883575] Google Scholar22. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302. [PMID: 2057034] Google Scholar23. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685-91. [PMID: 1463530] Google Scholar24. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997;349:747-52. [PMID: 9074572] Google Scholar25. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582-7. [PMID: 10821361] Google Scholar26. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-75. [PMID: 11759645] Google Scholar27. Maggioni AP, Anand I, Gottlieb SO, et al.; Val-HeFT Investigators (Valsartan Heart Failure Trial). Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol. 2002;40:1414-21. [PMID: 12392830] Google Scholar28. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362:772-6. [PMID: 13678870] Google Scholar29. Opie LH. Cellular basis for therapeutic choices in heart failure. Circulation. 2004;110(17):2559-61. [PMID: 15505109] Google Scholar30. Loeb HS, Johnson G, Henrick A, et al. Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation. 1993;87:VI78-87. [PMID: 8500244] Google Scholar31. Johnson G, Carson P, Francis GS, Cohn JN. Influence of prerandomization (baseline) variables on mortality and on the reduction of mortality by enalapril. Veterans Affairs Cooperative Study on Vasodilator Therapy of Heart Failure (V-HeFT II). V-HeFT VA Cooperative Studies Group. Circulation. 1993;87:VI32-9. [PMID: 8500237] Google Scholar32. African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049-57. [PMID: 15533851] Google Scholar33. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349-55. [PMID: 8614419] Google Scholar34. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation. 1994;90:1765-73. [PMID: 7923660] Google Scholar35. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9-13. [PMID: 10023943] Google Scholar36. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-7. [PMID: 10376614] Google Scholar37. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651-8. [PMID: 11386263] Google Scholar38. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-17. [PMID: 10471456] Google Scholar39. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-21. [PMID: 12668699] Google Scholar40. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351(6):543-51. [PMID: 15295047] Google Scholar41. Murray MD, Deer MM, Ferguson JA, et al. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med. 2001;111:513-20. [PMID: 11705426] Google Scholar42. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525-33. [PMID: 9036306] Google Scholar43. Khand AU, Rankin AC, Kaye GC, Cleland JG. Systematic review of the management of atrial fibrillation in patients with heart failure. Eur Heart J. 2000;21:614-32. [PMID: 10731399] Google Scholar44. Adams KF Jr, Gheorghiade M, Uretsky BF, et al. Clinical benefits of low serum digoxin concentrations in heart failure. J Am Coll Cardiol. 2002;39:946-53. [PMID: 11897434] Google Scholar45. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med. 2002;347:1403-11. [PMID: 12409542] Google Scholar46. How to diagnose diastolic heart failure. European Study Group on Diastolic Heart Failure. Eur Heart J. 1998;19:990-1003. [PMID: 9717033] Google Scholar47. Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350:2151-8. [PMID: 15152060] Google Scholar48. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-83. [PMID: 11907286] Google Scholar49. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225-37. [PMID: 15659722] Google Scholar50. Young JB, Abraham WT, Smith AL, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE ICD) Trial Investigators. JAMA. 2003;289:2685-94. [PMID: 12771115] Google Scholar51. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539-49. [PMID: 15753115] Google Scholar52. Dunkman WB, Johnson GR, Carson PE, et al. Incidence of thromboembolic events in congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation. 1993;87:VI94-101. [PMID: 8500246] Google Scholar53. Al-Khadra AS, Salem DN, Rand WM, et al. Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol. 1998;31:749-53. [PMID: 9525542] Google Scholar54. American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary. Circulation. 2001;104:2996-3007. [PMID: 11739319] Google Scholar55. American College of Cardiology. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society.Circulation. 2005;112:e154-235. [PMID: 16160202] Google Scholar56. Heart Failure Society of America. HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2006;12:e1-2. [PMID: 16500560] Google Scholar57. Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Panel; Department of Veterans Affairs, Veterans Health Administration. The Pharmacologic Management of Chronic Heart Failure. Accessed at http://www.oqp.med.va.gov/cpg/CHF/CHF_Base.htm on 11 October 2007. Google Scholar Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 4 December 2007Volume 147, Issue 11Page: ITC12-1KeywordsACE inhibitorsDeath ratesDiureticsEjection fractionExerciseHeart failureHospitalizationsImplantable cardioverter defibrillatorsLongitudinal studiesMortality ePublished: 4 December 2007 Issue Published: 4 December 2007 Copyright & PermissionsCopyright © 2007 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...